生物相似药市场:美国付款者的观点

本报告从新兴市场的角度介绍了美国生物相似药市场，强调了影响其未来的关键发展和课题。深入分析付款人对阿达木单抗采用和 Stelara 生物相似药推出的看法。深入了解 FDA 最新指导对可互换性的影响、自有品牌生物仿製药的作用以及付款人用来指导其定价和处方决策的策略。它还涵盖了生物相似药采用的障碍，例如监管不确定性和原创者策略，并全面概述了这些因素将如何影响市场趋势和医疗保健节省。

报告内容

• 过去一年发生的事件影响了付款人、医生和病人对生物相似药的看法
• 付款人对于阿达木单抗生物相似药的可用性有何反应？
• 付款人对 Stelara 生物相似药上市的看法
• 互换性将如何影响处方集的纳入以及还存在哪些课题？
• 自有品牌生物相似药对美国市场的影响
• 付款人如何看待药局层级的转换和替代等关键问题？
• 美国生物相似药市场有哪些障碍以及如何克服这些障碍？
• 付款人向生物相似药公司提供了哪些建议以帮助推动市场发展？

主要企业

Delve into the evolving landscape of the US biosimilars market, focusing on the significant developments and challenges that shape its future. This report provides an in-depth analysis of payer perspectives on the adoption of adalimumab and the anticipated launch of Stelara biosimilars. Gain insights into the impact of recent FDA guidance on interchangeability, the role of private-label co-branded biosimilars and the strategies payers employ to navigate pricing dynamics and formulary decisions. This report also addresses the barriers to biosimilar adoption, such as regulatory uncertainties and originator tactics, offering a comprehensive overview of how these factors influence market trends and healthcare savings.

Key Questions Answered:

• 1. What events have shaped the perception of biosimilars among payers, physicians, and patients in the past year?
• 2. How have payers responded to the coverage of adalimumab biosimilars?
• 3. What are payers' views on the upcoming launch of Stelara biosimilars?
• 4. How has interchangeability influenced formulary inclusions, and what challenges remain?
• 5. What is the impact of private-label co-branded biosimilars on the US market?
• 6. How do payers view key issues like switching and pharmacy-level substitution?
• 7. What barriers remain in the US biosimilars market, and how can they be overcome?
• 8. What advice do payers have for biosimilar companies to drive market evolution?

Key Companies:

Partial List of Participating Experts:

• Payer 1, medical director at a national insurance company that covers over 13 million lives
• Payer 2, chief medical officer at a regional managed care organisation with over 20 years of experience
• Payer 3, pharmacy director at a large national pharmacy benefit manager with 19 years of experience
• Payer 4, medical director with 20 years of experience at a managed care health plan covering 4.5 million lives and specialises in Medicaid business
• Payer 5, chief medical officer and chair of the pharmacy and therapeutics (P&T) committee at a leading managed care organisation with over 25 years of experience
• Payer 6, pharmacy director with 19 years of experience at a leading pharmacy benefit manager
• Payer 7, medical director at a national managed care organisation with over 30 years of experience
• Payer 8, director of pharmacy with over 20 years of experience in managed care, handling a national account with 45 million members, including 2 million Medicaid members

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.